ImmunityBio Director Granted 162,786 Stock Options at $2.84 Strike Price

ImmunityBio (IBRX) director Michael D. Blaszyk received a stock option grant on June 18, 2025.

Rhea-AI Filing Summary

ImmunityBio (IBRX) director Michael D. Blaszyk received a stock option grant on June 18, 2025. The key details of this insider transaction include:

• Granted 162,786 stock options to purchase common stock
• Exercise price set at $2.84 per share
• Options expire on June 18, 2035
• 100% of shares vest on the earlier of June 18, 2026 or the day before the next annual stockholder meeting
• Vesting is contingent on Blaszyk remaining a Service Provider under the company's 2025 Equity Incentive Plan

This Form 4 filing represents a standard director compensation equity grant, suggesting continued board engagement and alignment with shareholder interests through long-term equity incentives.

Insider Trade Summary

Grant/Award: 162,786 shares

Grant/Award 1 txn

Insider BLASZYK MICHAEL D

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	162,786	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 162,786 contracts (Direct)

Footnotes (1)

1. F1. Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 18, 2026 or the date immediately preceding the Issuer's next annual meeting of stockholders.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options did IBRX director Michael Blaszyk receive on June 18, 2025?

Michael Blaszyk received 162,786 stock options with an exercise price of $2.84 per share. These options were granted on June 18, 2025, and expire on June 18, 2035.

What are the vesting terms for IBRX director Blaszyk's 2025 stock options?

The stock options will vest 100% on the earlier of June 18, 2026, or the day before IBRX's next annual stockholder meeting, subject to Blaszyk remaining a Service Provider as defined in the company's 2025 Equity Incentive Plan.

How long does Michael Blaszyk have to exercise his IBRX stock options?

The stock options have a 10-year term, with an expiration date of June 18, 2035. They were granted with an exercise price of $2.84 per share.

What is Michael Blaszyk's role at IBRX according to the Form 4?

According to the Form 4 filing, Michael Blaszyk serves as a Director of ImmunityBio, Inc. (IBRX). He is not listed as an officer or 10% owner of the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/20/2025 - 06:34 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BLASZYK MICHAEL D

(Last) (First) (Middle)

C/O IMMUNITYBIO, INC.

3530 JOHN HOPKINS COURT

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ImmunityBio, Inc. [ IBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.84	06/18/2025		A		162,786		(1)	06/18/2035	Common Stock	162,786	$0	162,786	D

Explanation of Responses:

1. Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 18, 2026 or the date immediately preceding the Issuer's next annual meeting of stockholders.

Remarks:

	/s/ Jason Liljestrom, as Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.